Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Oct;350(4):410-5.
doi: 10.1007/BF00178960.

Endothelins induce prostacyclin release in both vascular and non-vascular tissue

Affiliations

Endothelins induce prostacyclin release in both vascular and non-vascular tissue

G G Mattera et al. Naunyn Schmiedebergs Arch Pharmacol. 1994 Oct.

Abstract

The effects of an i.v. administration of endothelin-1, -2 and -3 (0.25-3 nmol kg-1) or their corresponding proendothelins (1-20 nmol kg-1) on blood pressure and 6 keto-prostaglandin F1 alpha (6 keto-PGF1 alpha) release in the anaesthetized ganglion-blocked rat were evaluated. The same peptides were tested for their ability to release 6 keto-PGF1 alpha from the rat vas deferens in vitro. Endothelins and proendothelins showed a transient hypotensive effect followed by a potent, long lasting vasopressor response. Blood pressure increase induced by endothelins was found to be dose-dependently correlated with 6 keto-PGF1 alpha plasma level increases. On the other hand proendothelins produced similar pressor responses, but their effect on 6 keto-PGF1 alpha plasma levels was much less intense at equipressor doses. The effects of endothelins on arterial pressure and 6 keto-PGF1 alpha release were phosphoramidon-insensitive, while the activities of proendothelins were reduced by phosphoramidon (10 mg kg-1 i.v.). Both endothelins (5-15 nmol/l) and proendothelins (100-300 nmol/l) were able to increase to a similar extent 6 keto-PGF1 alpha levels in the rat vas deferens incubation buffer. The releasing activity of endothelins was not modified by the pretreatment with phosphoramidon (50 mumol/l). This pretreatment strongly inhibited proendothelin-1 and -2 effects, but not that of proendothelin-3.

PubMed Disclaimer

Similar articles

References

    1. Neuropeptides. 1993 Jan;24(1):35-42 - PubMed
    1. Eur J Pharmacol. 1990 Aug 21;185(1):103-6 - PubMed
    1. Eur J Pharmacol. 1990 Aug 21;185(1):25-33 - PubMed
    1. Biochem Pharmacol. 1989 Jun 15;38(12):1877-83 - PubMed
    1. Br J Pharmacol. 1989 Sep;98(1):38-40 - PubMed

Publication types